Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

#ESMO21 Expert Video Report on Melanoma

Reporting from the ESMO Congress 2021, Helen Gogas discusses the results of a phase II study of ipilimumab and nivolumab plus tocilizumab aiming to reverse steroid refractory toxicity from ICI in patients with metastatic melanoma. She also covers the MASTERKEY-265 phase III study testing the efficacy of pembrolizumab plus talimogene laherparepvec or placebo in advanced melanoma and the 3-year outcomes from the CheckMate 204 study of the nivolumab + ipilimumab combination in patients with brain metastases from melanoma.

Abstracts:
1040O - Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma - Dr Jeffrey Weber, US
1037O - MASTERKEY-265: A phase 3, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL) - Prof Helen Gogas, GR
1039MO - CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM) - Dr Kim Margolin, US

This video is part of a sponsored track. The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings